General Information
Ritter Pharmaceuticals Lactose Intolerance
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects with Lactose Intolerance.
| Protocol | G28-003 |
|---|---|
| Identifier | Site No: 05 |
| UID | 257204f7-45d7-4b94-a628-7b66d5e044cb |
| Status | Done - Archived |
| Phase | 2b/3 |
| Category | Lactose Intolerance / Adult |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2016-01-11 09:21 |
| Last Updated | 2016-01-11 09:21 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2016-03-14 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2016-03-14 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2017-04-26 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Sandoval, Larry | LSandoval | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Ritter Pharmaceuticals |
|---|---|
| Division | Ritter Pharmaceuticals |
| Team | Ritter Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Covance -LabCorp Drug Development |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
